COMMUNIQUÉS West-GlobeNewswire

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
18/09/2024
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) through [...]
Business update - opdatering på identitetsændring:
18/09/2024
Selskabet annoncerede i selskabsmeddelelse 13/2024, at man havde indledt en proces med at gennemføre et identitetsskifte med Nasdaq for fortsat at kunne bevare sin status som børsnoteret selskab. Nasdaq har dags dato [...]
SupplyCopia Unveils Groundbreaking AI Solutions at AHRMM24
18/09/2024
Transforming Healthcare Supply Chains and Driving CQO Through AI Innovation BRIDGEWATER, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- SupplyCopia is thrilled to announce its participation at the AHRMM24 Conference, where it [...]
Marius Pharmaceuticals Partners with UK-Based Numan to Combat Testosterone Deficiency with KYZATREX® (Testosterone Undecanoate) CIII Capsules
18/09/2024
RALEIGH, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce a new partnership with Numan , a leading UK-based, VC-backed digital health platform, to introduce KYZATREX ® (testosterone [...]
Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan
18/09/2024
PALO ALTO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
GRI Bio Participates in Virtual Investor KOL Connect Segment
18/09/2024
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey, Respiratory Consultant at [...]
NEXGEL's Beauty Brand, Silly George, Partners with Multi-Talented Artist and Entrepreneur, James Maslow, to Promote Innovative Eyelash Collection
18/09/2024
LANGHORNE, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
Corza Medical Named to the 2024 MedTech Big 100 List
18/09/2024
WESTWOOD, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Corza Medical (“Corza” or the “Company”), a leading global medical technology company committed to remarkable service, trusted performance and outstanding value, is [...]
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
18/09/2024
- Transaction Will Maximize the Access and Uptake of COSELA ® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark [...]
Notice of Annual General Meeting 2024
18/09/2024
ANNOUNCEMENT NO. 275 18 September 2024 Notice of Annual General Meeting Notice is hereby given of the Annual General Meeting, which will be held on Thursday 10 October 2024 at 5.30 p.m. The general meeting will be held [...]
Revolo Announces New Preclinical Data Further Validating Atopic Dermatitis as a Target Indication for ‘1104
18/09/2024
Data continues to differentiate ‘1104 as a potential allergic disease treatment that acts upstream in the immune cascade ‘1104 reduces key indices of skin inflammation and inflammatory mediators in a chronic allergen- [...]
Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024
18/09/2024
Presentations Will Highlight Oral Prolonged-Release Ketamine (KET01) And its Minimal Impact on Sleep, Alongside Excellent Day-One Tolerability in Patients MUNICH, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“ [...]
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18/09/2024
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Sonnet [...]
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
18/09/2024
New Biological Data Released from IRO® Cell Therapy Manufacturing Platform PHILADELPHIA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing enabling technology, [...]
Femasys Announces Infertility Clinic Customers from Coast to Coast
18/09/2024
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing [...]
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
18/09/2024
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today [...]
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
18/09/2024
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative [...]
Procaps Issues Shareholder Letter Update
18/09/2024
MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the [...]
Kairos Pharma Closing of $6.2 Million Initial Public Offering
17/09/2024
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse [...]

Pages